Brief: Ascelia Pharma Q3 Operating Loss Widens To SEK 32.7 Mln

Ascelia Pharma AB

04/11/2021 07:12

Nov 4 (Reuters) - Ascelia Pharma AB  ACELP.ST :
    * GUIDANCE FOR EXPECTED RECRUITMENT COMPLETION TO SPARLE
TRIAL WAS
EXTENDED TO H1 2022 (PREVIOUSLY H2 2021)
    * Q3 OPERATING RESULT OF SEK -32.7M (SEK -16.3M)
    * Q3 EARNINGS PER SHARE OF SEK -0.82 (SEK -0.51)

Source text for Eikon:  ID:nMFN2j2htN 
Further company coverage:  ACELP.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))